Yoon et al. [20] showed that heterogeneous HER2 amplification in oesophageal adenocarcinoma independently predicted worse disease-specific survival and overall survival compared to non-heterogeneous HER2 amplified tumours. The gene discussed is ERBB2; the disease is neoplasm.